Predicted protein targets (top 15)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | DNM1 | Q05193 | 3/20 | 0.41 |
| ▸ | LMNA | P02545 | 1/20 | 0.36 |
| ▸ | PKM | P14618 | 1/20 | 0.36 |
| ▸ | SMN1; SMN2 | Q16637 | 1/20 | 0.36 |
| ▸ | GPR84 | Q9NQS5 | 2/20 | 0.36 |
| ▸ | TLR8 | Q9NR97 | 3/20 | 0.35 |
| ▸ | TLR7 | Q9NYK1 | 2/20 | 0.35 |
| ▸ | PTPN11 | Q06124 | 1/20 | 0.35 |
| ▸ | EHMT2 | Q96KQ7 | 2/20 | 0.34 |
| ▸ | EHMT1 | Q9H9B1 | 2/20 | 0.34 |
| ▸ | NOS1 | P29475 | 1/20 | 0.33 |
| ▸ | HRH3 | Q9Y5N1 | 1/20 | 0.33 |
| ▸ | DHFR | P00374 | 1/20 | 0.33 |
| ▸ | CDK1 | P06493 | 1/20 | 0.33 |
| ▸ | CCNB1 | P14635 | 1/20 | 0.33 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL9618286 | 0.98 | DNM1 (0.38) | DNM1LMNAPKMSMN1; SMN2GPR84 | |
| SCHEMBL4419657 | 0.92 | PTPN11 (0.39) | LMNAPKMSMN1; SMN2TLR8TLR7 | |
| SCHEMBL14869532 | 0.89 | LMNA (0.39) | DNM1LMNAPKMSMN1; SMN2TLR8 | |
| SCHEMBL14869444 | 0.87 | HSP90AA1 (0.37) | DNM1LMNAPKMSMN1; SMN2TLR8 | |
| SCHEMBL14441524 | 0.86 | DNM1 (0.50) | DNM1GPR84EHMT2EHMT1 | |
| SCHEMBL14441520 | 0.86 | DNM1 (0.50) | DNM1GPR84EHMT2EHMT1 | |
| SCHEMBL14441522 | 0.86 | DNM1 (0.50) | DNM1GPR84EHMT2EHMT1 | |
| SCHEMBL14441521 | 0.86 | DNM1 (0.50) | DNM1GPR84EHMT2EHMT1 | |
| SCHEMBL14869506 | 0.84 | CA1 (0.40) | LMNAPKMSMN1; SMN2TLR8TLR7 | |
| SCHEMBL14869351 | 0.83 | CA1 (0.35) | DNM1LMNAPKMSMN1; SMN2TLR8 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 8 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20090041715-A1 | Epothilone Combinations | NOVARTIS AG (CH) | 2009-02-12 | — | — | US | claimed |
| CN-1988904-A | Epothilone combinations | NOVARTIS AG (CH) | 2007-06-27 | — | — | CN | claimed |
| EP-1773334-A1 | EPOTHILONE COMBINATIONS | Novartis AG (CH) | 2007-04-18 | — | — | EP | claimed |
| WO-2006010585-A1 | EPOTHILONE COMBINATIONS | NOVARTIS AG (CH) | 2006-02-02 | — | — | WO | claimed |
| US-20090041715-A1 | Epothilone Combinations | NOVARTIS AG (CH) | 2009-02-12 | — | — | US | disclosed |
| CN-1988904-A | Epothilone combinations | NOVARTIS AG (CH) | 2007-06-27 | — | — | CN | disclosed |
| EP-1773334-A1 | EPOTHILONE COMBINATIONS | Novartis AG (CH) | 2007-04-18 | — | — | EP | disclosed |
| WO-2006010585-A1 | EPOTHILONE COMBINATIONS | NOVARTIS AG (CH) | 2006-02-02 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20090041715-A1 | Epothilone Combinations | EPOR, ETV6, ERAL1 | DNM1 2062/4885LMNA 2801/4885PKM 3054/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.